Drug Profile
CP 506
Alternative Names: CP-506Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator University of Auckland
- Developer Convert Pharmaceuticals; University of Auckland
- Class Antineoplastics; Small molecules
- Mechanism of Action Alkylating agents; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Feb 2024 CP 506 is still in preclinical studies for Cancer in Belgium (Convert Pharmaceuticals pipeline, February 2024)
- 29 Feb 2024 Pharmacodynamics data from preclinical studies in Cancer released by Convert Pharmaceuticals (Convert Pharmaceuticals pipeline, February 2024)
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in Belgium (Intraperitoneal)